New Mexico Educational Retirement Board boosted its holdings in Omnicell, Inc. (NASDAQ:OMCL – Free Report) by 12.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,100 shares of the company’s stock after acquiring an additional 1,000 shares during the period. New Mexico Educational Retirement Board’s holdings in Omnicell were worth $670,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also recently added to or reduced their stakes in OMCL. Wellington Management Group LLP grew its stake in Omnicell by 16.4% in the 1st quarter. Wellington Management Group LLP now owns 3,815,052 shares of the company’s stock valued at $223,829,000 after acquiring an additional 537,452 shares during the last quarter. Norges Bank purchased a new stake in Omnicell in the 4th quarter valued at approximately $22,291,000. Champlain Investment Partners LLC lifted its stake in Omnicell by 40.0% in the 1st quarter. Champlain Investment Partners LLC now owns 983,995 shares of the company’s stock valued at $57,731,000 after buying an additional 281,305 shares in the last quarter. Rockefeller Capital Management L.P. lifted its stake in Omnicell by 698.2% in the 1st quarter. Rockefeller Capital Management L.P. now owns 272,768 shares of the company’s stock valued at $16,003,000 after buying an additional 238,593 shares in the last quarter. Finally, Granite Investment Partners LLC lifted its stake in Omnicell by 289.5% in the 1st quarter. Granite Investment Partners LLC now owns 309,855 shares of the company’s stock valued at $18,179,000 after buying an additional 230,295 shares in the last quarter. 99.18% of the stock is owned by institutional investors and hedge funds.
Omnicell Trading Down 1.7 %
OMCL stock opened at $44.41 on Wednesday. Omnicell, Inc. has a 52 week low of $44.05 and a 52 week high of $91.99. The company has a market cap of $2.01 billion, a price-to-earnings ratio of -85.40, a PEG ratio of 6.60 and a beta of 0.89. The company has a quick ratio of 2.03, a current ratio of 2.38 and a debt-to-equity ratio of 0.49. The business has a fifty day simple moving average of $57.11 and a 200-day simple moving average of $63.28.
Wall Street Analyst Weigh In
Several brokerages recently weighed in on OMCL. Benchmark cut their target price on shares of Omnicell from $88.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday. KeyCorp cut their target price on shares of Omnicell from $80.00 to $75.00 and set an “overweight” rating for the company in a research note on Friday, August 4th. StockNews.com began coverage on shares of Omnicell in a research note on Thursday, August 17th. They issued a “hold” rating for the company. Piper Sandler cut shares of Omnicell from an “overweight” rating to a “neutral” rating and lifted their target price for the stock from $66.00 to $70.00 in a research note on Wednesday, August 2nd. Finally, Wells Fargo & Company lowered their target price on shares of Omnicell from $56.00 to $39.00 and set an “underweight” rating for the company in a research note on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Omnicell presently has an average rating of “Hold” and a consensus target price of $64.38.
Read Our Latest Report on OMCL
About Omnicell
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
See Also
- Five stocks we like better than Omnicell
- Dividend Payout Ratio Calculator
- Why Ralph Lauren Should Be On Your Holiday Wishlist
- Financial Services Stocks Investing
- MarketBeat Stock of the Week, Amazon Goes Big on AI
- The Significance of Brokerage Rankings in Stock Selection
- Inflation is Why a Soft Landing is Bad for the Economy
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL – Free Report).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.
